The scale of infections has led to predictions of very high sales for the first RSV vaccines to reach the market, with analysts at SVB Leerink predicting the market could reach upwards of $10 ...

Analysts at SVB Leerink said that while the offer is fair at that price, Alexion is a “scarce and high-quality asset,” which could prompt an offer from another company. In the past ...

Leerink Partnrs also issued estimates for NeuroPace’s Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.51) EPS, FY2027 ...

Leerink Partnrs analyst M. Cherny now expects that the medical research company will earn $2.58 per share for the quarter, down from their prior estimate of $2.59. Leerink Partnrs currently has a ...

Leerink Partners analyst Michael Cherny reiterated a Hold rating on Certara (CERT – Research Report) on April 11. The company’s shares closed last Friday at $12.91. Discover outperforming ...

Leerink analyst Faisal Khurshid lowered the firm’s price target on Ironwood (IRWD) to $1 from $3 and keeps a Market Perform rating on the shares after the company announced they will need to run ...

Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (LSE:0A4D) from Outperform to Market Perform. There are 35 funds or institutions reporting positions ...

J.P. Morgan analyst Anne E. Samuel reiterated the Neutral rating on Premier, Inc. (NASDAQ:PINC) on Tuesday, with a price forecast of $19. The analyst notes that Premier’s stable business is ...

Fintel reports that on April 8, 2025, Leerink Partners initiated coverage of Spyre Therapeutics (NasdaqGS:SYRE) with a Outperform recommendation. As of April 2, 2025, the average one-year price ...

On Tuesday, Leerink Partners maintained its Outperform rating on CVS Health (NYSE:CVS) shares with a steady price target of $75.00. According to InvestingPro data, CVS Health, currently trading at ...